Medicine guide
Telmisartan Actavis
- Prescription status not stated
- Heart, blood pressure and circulation
- Active substance
- Telmisartan
- Made by
- Actavis Group PTC ehf
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Telmisartan Actavis contains the active substance telmisartan which belongs to a class of medicines known as angiotensin II receptor antagonists.
- Angiotensin II is a substance produced in your body, which causes your blood vessels to narrow, thus increasing your blood pressure. Telmisartan Actavis blocks the effect of angiotensin II so that the blood vessels relax, and your blood pressure is lowered.
- Telmisartan Actavis tablets are used to treat essential hypertension (high blood pressure) in adults.
- ‘Essential’ means that the high blood pressure is not caused by any other condition.
- High blood pressure, if not treated, can damage blood vessels in several organs which could lead sometimes to heart attacks, heart or kidney failure, strokes or blindness. There are usually no symptoms of high blood pressure before damage occurs. Thus it is important to regularly measure blood pressure to verify if it is within the normal range.
- Telmisartan Actavis is also used to reduce cardiovascular events (i.e. heart attack or stroke) in adults who are at risk because they have a reduced or blocked blood supply to the heart or legs, or have had a stroke or have high risk diabetes. Your doctor can tell you if you are at high risk for such events.
From the package leaflet in EMA’s product information, p. 43 · 2026-07-07
How it works
From the US prescribing label for the same active substance (Telmisartan). It describes the substance, not this exact product.
Angiotensin II is formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II).
Angiotensin II is the principal pressor agent of the renin-angiotensin system, with effects that include vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium.
Peak level after0.5–1 h
Half-life24 h
Mostly cleared after≈ 5 daysfive half-lives — our arithmetic
How the body breaks it down
Telmisartan is metabolized by conjugation to form a pharmacologically inactive acyl glucuronide; the glucuronide of the parent compound is the only metabolite that has been identified in human plasma and urine.
With food
Food slightly reduces the bioavailability of telmisartan, with a reduction in the area under the plasma concentration-time curve (AUC) of about 6% with the 40 mg tablet and about 20% after a 160 mg dose.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-08-11
Do not take it if
- if you are allergic to telmisartan or any other ingredients of this medicine (listed in section 6).
- If you are more than 3 months pregnant. (It is also better to avoid Telmisartan Actavis in early pregnancy – see pregnancy section.)
- if you have severe liver problems such as cholestasis or biliary obstruction (problems with the drainage of the bile from the liver and gall bladder) or any other severe liver disease.
- if you have diabetes or impaired kidney function and you are treated with a blood pressure lowering medicine containing aliskiren.
- If any of the above applies to you, tell your doctor or pharmacist before taking Telmisartan Actavis.
- Warning and precautions Talk to your doctor if you are suffering or have ever suffered from any of the following conditions or illnesses:
- Kidney disease or kidney transplant.
- Renal artery stenosis (narrowing of the blood vessels to one or both kidneys).
- Liver disease.
- Heart trouble.
- Raised aldosterone levels (water and salt retention in the body along with imbalance of various blood minerals).
- Low blood pressure (hypotension), likely to occur if you are dehydrated (excessive loss of body water) or have salt deficiency due to diuretic therapy ('water tablets'), low-salt diet, diarrhoea, or vomiting.
- Elevated potassium levels in your blood.
- Diabetes.
- Talk to your doctor before taking Telmisartan Actavis:
- if you are taking digoxin.
- if you are taking any of the following medicines used to treat high blood pressure:
- an ACE-inhibitor (for example enalapril, lisinopril, ramipril), in particular if you have diabetes-related kidney problems.
- aliskiren.
- Your doctor may check your kidney function, blood pressure, and the amount of electrolytes (e.g.
- potassium) in your blood at regular intervals.
- See also information under the heading “Do not take Telmisartan Actavis”.
- Talk to your doctor if you experience abdominal pain, nausea, vomiting or diarrhoea after taking Telmisartan Actavis. Your doctor will decide on further treatment. Do not stop taking Telmisartan Actavis on your own.
- You must tell your doctor if you think you are (or might become) pregnant. Telmisartan Actavis is not recommended in early pregnancy, and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if used at that stage (see pregnancy section).
- In case of surgery or anaesthesia, you should tell your doctor that you are taking Telmisartan Actavis.
- Telmisartan Actavis may be less effective in lowering the blood pressure in black patients.
- Children and adolescents The use of Telmisartan Actavis in children and adolescents up to the age of 18 years is not recommended.
From the package leaflet in EMA’s product information, p. 43–44.
How to take it
These directions are for this exact strength and form. Another one is different.
- Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.
- For treatment of high blood pressure, the usual dose of Telmisartan Actavis for most patients is one 40 mg tablet once a day to control blood pressure over the 24-hour period. Your doctor has recommended a lower dose of one 20 mg tablet daily. Telmisartan Actavis may also be used in combination with diuretics (‘water tablets’) such as hydrochlorothiazide which has been shown to have an additive blood pressure lowering effect with telmisartan.
- For reduction of cardiovascular events, the usual dose of Telmisartan Actavis is one 80 mg tablet once a day. At the beginning of the preventive therapy with Telmisartan Actavis 80 mg, blood pressure should be frequently monitored.
- In patients with liver problems the usual dose should not exceed 40 mg once daily.
- In patients with kidney problems a lower starting dose of 20 mg is recommended.
- Try to take the tablet at the same time each day. You can take Telmisartan Actavis with or without food. The tablets should be swallowed with some water or other non-alcoholic drink. It is important that you take Telmisartan Actavis every day until your doctor tells you otherwise. If you have the impression that the effect of Telmisartan Actavis is too strong or too weak, talk to your doctor or pharmacist.
- If you take more Telmisartan Actavis than you should It is important to keep to the dose as prescribed by your doctor. If you accidentally take too many tablets ask your doctor what to do or contact your nearest hospital emergency department immediately.
- The most common symptoms of telmisartan overdose are low blood pressure (hypotension) and fast heart beat (tachycardia). Slow heart beat (bradycardia), dizziness, higher levels of creatinine in the blood and sudden kidney failure have also been reported.
- If you forget to take Telmisartan Actavis If you forget to take your medicine you should take the dose as soon as you remember on the same day. If you do not take your tablet on one day, take your normal dose on the next day. Do not take a double dose to make up for a forgotten dose.
- If you stop taking Telmisartan Actavis Take Telmisartan Actavis every day for as long as your doctor prescribes it in order to keep your blood pressure controlled. If you have the impression that the effect of Telmisartan Actavis is too strong or too weak, talk to your doctor or pharmacist.
- If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
From the package leaflet in EMA’s product information, p. 45–46.
Pregnancy and breastfeeding
- You must tell your doctor if you think you are (or might become) pregnant. Your doctor will normally advise you to stop taking Telmisartan Actavis before you become pregnant or as soon as you know you are pregnant and will advise you to take another medicine instead of Telmisartan Actavis. Telmisartan Actavis is not recommended in early pregnancy, and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if used after the third month of pregnancy.
- Breast-feeding Tell your doctor if you are breast-feeding or about to start breast-feeding. Telmisartan Actavis is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast-feed, especially if your baby is newborn, or was born prematurely.
From the package leaflet in EMA’s product information, p. 45.
Other medicines
- Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
- Your doctor may need to change the dose of these other medicines or take other precautions. In some cases you may have to stop taking one of the medicines. This applies especially to the medicines listed below taken at the same time with Telmisartan Actavis
- Lithium containing medicines to treat some types of depression.
- Medicines that may increase blood potassium levels such as salt substitutes containing potassium, potassium-sparing diuretics (certain 'water tablets'), ACE inhibitors (angiotensin- converting enzyme inhibitors, to treat high blood pressure), angiotensin II receptor antagonists (to treat high blood pressure), NSAIDs (non steroidal anti-inflammatory medicines, e.g. aspirin or ibuprofen), heparin (a medicine for thinning the blood), immunosuppressives (e.g.
- cyclosporin or tacrolimus), and the antibiotic trimethoprim.
- Diuretics ('water tablets'), especially if taken in high doses together with Telmisartan Actavis, may lead to excessive loss of body water and low blood pressure (hypotension).
- If you are taking an ACE-inhibitor or aliskiren (see also information under the headings “Do not take Telmisartan Actavis” and “Warnings and precautions”).
- Digoxin.
- The effect of Telmisartan Actavis may be reduced when you take NSAIDs (non steroidal anti-inflammatory drugs, e.g. aspirin or ibuprofen) or corticosteroids.
- Telmisartan Actavis may increase the blood pressure lowering effect of other medicines used to treat high blood pressure or of medicines with blood pressure lowering potential (e.g. baclofen, amifostine).
- Furthermore, low blood pressure may be aggravated by alcohol, barbiturates, narcotics or antidepressants. You may notice this as dizziness when standing up. You should consult with your doctor if you need to adjust the dose of your other medicine while taking Telmisartan Actavis.
From the package leaflet in EMA’s product information, p. 44–45.
Driving and using machines
- Some people feel dizzy or tired when taking Telmisartan Actavis. If you feel dizzy or tired, do not drive or use machines.
- Telmisartan Actavis contains sodium.
- This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially ‘sodium- free’.
From the package leaflet in EMA’s product information, p. 45.
Side effects
- Like all medicines, this medicine can cause side effects, although not everybody gets them.
- Some side effects can be serious and need immediate medical attention:
- You should see your doctor immediately if you experience any of the following symptoms:
- Sepsis* (often called "blood poisoning", is a severe infection with whole-body inflammatory response), rapid swelling of the skin and mucosa (angioedema); these side effects are rare (may affect up to 1 in 1,000 people) but are extremely serious and patients should stop taking the medicine and see their doctor immediately. If these effects are not treated they could be fatal.
- Possible side effects of telmisartan:
- Common side effects (may affect up to 1 in 10 people):
- Low blood pressure (hypotension) in users treated for reduction of cardiovascular events.
- Uncommon side effects (may affect up to 1 in 100 people):
- Urinary tract infections, upper respiratory tract infections (e.g. sore throat, inflamed sinuses, common cold), deficiency in red blood cells (anaemia), high potassium levels, difficulty falling asleep, feeling sad (depression), fainting (syncope), dizziness, feeling of spinning (vertigo), slow heart rate (bradycardia), low blood pressure (hypotension) in users treated for high blood pressure, dizziness on standing up (orthostatic hypotension), shortness of breath, cough, abdominal pain, diarrhoea, discomfort in the abdomen, bloating, vomiting, itching, increased sweating, drug rash, back pain, muscle cramps, muscle pain (myalgia), kidney impairment including acute kidney failure, pain in the chest, feeling of weakness, and increased level of creatinine in the blood.
- Rare side effects (may affect up to 1 in 1,000 people):
- Sepsis* (often called "blood poisoning", is a severe infection with whole-body inflammatory response which can lead to death), increase in certain white blood cells (eosinophilia), low platelet count (thrombocytopenia), severe allergic reaction (anaphylactic reaction), allergic reaction (e.g. rash, itching, difficulty breathing, wheezing, swelling of the face or low blood pressure), low blood sugar levels (in diabetic patients), feeling anxious, somnolence, impaired vision, fast heart beat (tachycardia), dry mouth, upset stomach, taste disturbance (dysgeusia), abnormal liver function (Japanese patients are more likely to experience this side effect), rapid swelling of the skin and mucosa which can also lead to death (angioedema also with fatal outcome), eczema (a skin disorder), redness of skin, hives (urticaria), severe drug rash, joint pain (arthralgia), pain in extremity, tendon pain, flu-like-illness, decreased haemoglobin (a blood protein), increased levels of uric acid, increased hepatic enzymes or creatine phosphokinase in the blood.
- Very rare side effects (may affect up to 1 in 10,000 people):
- Progressive scarring of lung tissue (interstitial lung disease)**.
- Frequency ‘not known’ (frequency cannot be estimated from the available data):
- Intestinal angioedema: A swelling in the gut presenting with symptoms like abdominal pain, nausea, vomiting and diarrhoea have been reported after the use of similar products.
- * The event may have happened by chance or could be related to a way that telmisartan works that is currently not known.
- **Cases of progressive scarring of lung tissue have been reported during intake of telmisartan.
- However, it is not known whether telmisartan was the cause.
- Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
From the package leaflet in EMA’s product information, p. 46–47.
How to store it
- Keep this medicine out of the sight and reach of children.
- Do not use this medicine after the expiry date which is stated on the carton, bottle or blister after “EXP”. The expiry date refers to the last day of that month.
- Al/Al blisters:
- Store in the original package in order to protect from light.
- HDPE tablet container:
- Keep the container tightly closed in order to protect from light.
- Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
From the package leaflet in EMA’s product information, p. 47.
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
SpainNo exact match for this strength and form
FranceNo exact match for this strength and form
CanadaNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
SwitzerlandNo exact match for this strength and form
Details
| Made by | Actavis Group PTC ehf |
|---|---|
| Active substance | Telmisartan |
| Used in | Heart, blood pressure and circulation |
| Classification | C09CA07 · Heart, blood pressure and circulation |
| Generic | Yes — a generic medicine, according to the register |
| Authorised on | 2010-09-29 |
| Last updated by the regulator | 2026-07-07 |
| EMA product number | EMEA/H/C/001168 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.
ToluraEU authorisation Krka, d.d., Novo mesto · Telmisartan · C09CA07MicardisEU authorisation Boehringer Ingelheim International GmbH · Telmisartan · C09CA07Kinzalmono (previously Telmisartan Boehringer Ingelheim Pharma KG)EU authorisation Bayer AG · Telmisartan · C09CA07PritorEU authorisation Bayer AG · Telmisartan · C09CA07Telmisartan Teva PharmaEU authorisation Teva B.V. · Telmisartan · C09CA07Telmisartan TevaEU authorisation Teva B.V. · Telmisartan · C09CA07